Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
Autor: | Mark Jahn, Bobbie Smith, Serban-Dan Costa, Udo Altmann, Atanas Ignatov, Gunter von Minckwitz, Holm Eggemann, Freidrich W. Röhl |
---|---|
Rok vydání: | 2012 |
Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Antineoplastic Agents Hormonal medicine.drug_class medicine.medical_treatment Breast Neoplasms Male Breast cancer Germany Internal medicine Adjuvant therapy Humans Medicine Aromatase skin and connective tissue diseases Aged Aged 80 and over Chemotherapy Aromatase inhibitor biology Aromatase Inhibitors business.industry Cancer Middle Aged medicine.disease Tamoxifen Treatment Outcome Receptors Estrogen Chemotherapy Adjuvant Male breast cancer biology.protein business Follow-Up Studies medicine.drug |
Zdroj: | Breast Cancer Research and Treatment. 137:465-470 |
ISSN: | 1573-7217 0167-6806 |
DOI: | 10.1007/s10549-012-2355-3 |
Popis: | To determine the impact of adjuvant treatment with tamoxifen and aromatase inhibitors (AI) on the survival of men with breast cancer. We analyzed 257 male patients with hormone-receptor-positive breast cancer from numerous German population-based cancer registries treated with tamoxifen (N = 207) or aromatase inhibitors (N = 50). The median follow-up was 42.2 (range 2-115) months. Median age at diagnosis was 68 (range 36-91) years. Thirty-seven (17.9 %) patients treated with tamoxifen and 16 (32.0 %) patients treated with AI died (log rank p = 0.007). After the adjustment for the patient's age, tumor size, node status, and tumor grading, the AI treatment was linked to a 1.5-fold increase in risk of mortality compared to tamoxifen (HR 1.55; 95 % CI: 1.13-2.13; p = 0.007). The overall survival in male breast cancer was significantly better after adjuvant treatment with tamoxifen compared to an aromatase inhibitor. Tamoxifen should be considered as the treatment of choice for hormone-receptor-positive male breast cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |